RNF2 and cancer: RING1B is the more commonly upregulated RING paralog in cancer, and as the catalytic subunit of PRC1, represents a good therapeutic target (Figure 4); in contrast, RING1A is commonly downregulated in cancers and low expression correlates with poor prognosis, indicating that it may act as a tumor suppressor (200).